Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

There is a growing search for therapeutic targets in the treatment of gout. The present study aimed to evaluate the analgesic and anti-inflammatory potential of angiotensin type 2 receptor (AT2R) antagonism in an acute gout attack mouse model. Male wild-type (WT) C57BL/6 mice either with the AT2R antagonist, PD123319 (10 pmol/joint), or with vehicle injections, or AT2R KO mice, received intra-articular (IA) injection of monosodium urate (MSU) crystals (100 µg/joint), that induce the acute gout attack, and were tested for mechanical allodynia, thermal hyperalgesia, spontaneous nociception and ankle edema development at several times after the injections. To test an involvement of AT2R in joint pain, mice received an IA administration of angiotensin II (0.05-5 nmol/joint) with or without PD123319, and were also evaluated for pain and edema development. Ankle joint tissue samples from mice undergoing the above treatments were assessed for myeloperoxidase activity, IL-1β release, mRNA expression analyses and nitrite/nitrate levels, 4 h after injections. AT2R antagonism has robust antinociceptive effects on mechanical allodynia (44% reduction) and spontaneous nociception (56%), as well as anti-inflammatory effects preventing edema formation (45%), reducing myeloperoxidase activity (54%) and IL-1β levels (32%). Additionally, Agtr2tm1a mutant mice have largely reduced painful signs of gout. Angiotensin II administration causes pain and inflammation, which was prevented by AT2R antagonism, as observed in mechanical allodynia 4 h (100%), spontaneous nociception (46%), cold nociceptive response (54%), edema formation (83%), myeloperoxidase activity (48%), and IL-1β levels (89%). PD123319 treatment also reduces NO concentrations (74%) and AT2R mRNA levels in comparison with MSU untreated mice. Our findings show that AT2R activation contributes to acute pain in experimental mouse models of gout. Therefore, the antagonism of AT2R may be a potential therapeutic option to manage gout arthritis. © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.


Thiago Neves Vieira, André L Lopes Saraiva, Rafaela Mano Guimarães, João Paulo Mesquita Luiz, Larissa Garcia Pinto, Veridiana de Melo Rodrigues Ávila, Luiz Ricardo Goulart, Jair Pereira Cunha-Junior, Peter Anthony McNaughton, Thiago Mattar Cunha, Juliano Ferreira, Cassia Regina Silva. Angiotensin type 2 receptor antagonism as a new target to manage gout. Inflammopharmacology. 2022 Dec;30(6):2399-2410

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 36173505

View Full Text